Your browser is no longer supported. Please, upgrade your browser.
HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsElite Help
publish chart | save to portfolio | create alert Type: candle | line | advanced | interactive | perf    Timeframe: intraday | daily | weekly | monthly  Settings
MRK Merck & Co., Inc. daily Stock Chart
MRK [NYSE]
Merck & Co., Inc.
Healthcare | Drug Manufacturers - Major | USA
statements
IndexDJIA S&P500 P/E22.79 EPS (ttm)3.71 Insider Own0.10% Shs Outstand2.57B Perf Week-0.20%
Market Cap217.55B Forward P/E15.41 EPS next Y5.48 Insider Trans-10.90% Shs Float2.56B Perf Month-0.75%
Income9.72B PEG2.54 EPS next Q1.24 Inst Own78.10% Short Float0.84% Perf Quarter3.04%
Sales44.37B P/S4.90 EPS this Y33.00% Inst Trans-0.05% Short Ratio2.60 Perf Half Y13.30%
Book/sh10.74 P/B7.87 EPS next Y11.35% ROA11.20% Target Price95.93 Perf Year17.05%
Cash/sh2.76 P/C30.62 EPS next 5Y8.98% ROE32.80% 52W Range66.10 - 87.35 Perf YTD10.61%
Dividend2.20 P/FCF91.10 EPS past 5Y10.60% ROI11.70% 52W High-3.24% Beta0.55
Dividend %2.60% Quick Ratio0.90 Sales past 5Y-0.80% Gross Margin71.10% 52W Low27.87% ATR1.25
Employees69000 Current Ratio1.20 Sales Q/Q12.40% Oper. Margin26.70% RSI (14)50.85 Volatility1.03% 1.48%
OptionableYes Debt/Eq0.96 EPS Q/Q62.90% Profit Margin21.10% Rel Volume0.62 Prev Close84.68
ShortableYes LT Debt/Eq0.82 EarningsOct 29 BMO Payout59.20% Avg Volume8.25M Price84.52
Recom1.80 SMA200.76% SMA500.05% SMA2004.10% Volume5,089,060 Change-0.19%
Oct-17-19Resumed BofA/Merrill Neutral $90
Aug-16-19Initiated SVB Leerink Outperform
Jul-03-19Initiated Mizuho Buy $97
May-28-19Initiated Goldman Neutral
May-13-19Upgrade Atlantic Equities Neutral → Overweight
Oct-16-18Reiterated Citigroup Buy $70 → $79
Oct-09-18Resumed Guggenheim Buy
Apr-23-18Upgrade Goldman Neutral → Buy
Apr-17-18Upgrade Morgan Stanley Equal-Weight → Overweight
Apr-05-18Upgrade Barclays Equal Weight → Overweight $62 → $64
Mar-12-18Upgrade Leerink Partners Mkt Perform → Outperform
Feb-14-18Reiterated Leerink Partners Mkt Perform $67 → $66
Feb-07-18Reiterated Morgan Stanley Equal-Weight $60 → $63
Jan-16-18Upgrade SunTrust Hold → Buy
Nov-28-17Resumed BofA/Merrill Buy $64
Nov-24-17Reiterated Deutsche Bank Hold $62 → $59
Oct-31-17Upgrade Jefferies Underperform → Hold
Oct-30-17Downgrade SunTrust Buy → Hold
Oct-30-17Downgrade Morgan Stanley Overweight → Equal-Weight
Oct-30-17Downgrade Barclays Overweight → Equal Weight $72 → $62
Oct-21-19 04:30PM  NewLink Genetics Announces EU Regulatory Committee (CHMP) Recommendation for Conditional Marketing Authorization for Ebola Vaccine V920 (ERVEBO®) GlobeNewswire
12:14PM  What's in the Cards for AstraZeneca (AZN) in Q3 Earnings? Zacks
11:00AM  What's in Store for Healthcare ETFs in Q3 Earnings? Zacks
10:38AM  The Zacks Analyst Blog Highlights: Procter & Gamble, United Technologies, Boeing, Merck & Co. and Apple Zacks
05:53AM  With $50M raise, Bedford startup seeks treatments for 75 percent of cancers American City Business Journals
Oct-18-19 11:17AM  Will Strong HIV Sales Drive Gilead's (GILD) Q3 Earnings? Zacks
10:21AM  Factors Setting the Tone for Novartis' (NVS) Q3 Earnings Zacks
09:15AM  Are You Looking for a High-Growth Dividend Stock? Merck (MRK) Could Be a Great Choice Zacks
07:23AM  5 Dow Stocks Poised to Beat on Earnings This Month Zacks
07:15AM  Merck gets EU panel nod for first ever Ebola vaccine Reuters
07:00AM  Merck Receives Positive EU CHMP Opinion for Two New Regimens of KEYTRUDA® (pembrolizumab) as First-Line Treatment for Metastatic or Unresectable Recurrent Head and Neck Squamous Cell Carcinoma Business Wire
06:45AM  Merck Receives EU CHMP Positive Opinion for Investigational V920 Ebola Zaire Vaccine for Protection Against Ebola Virus Disease Business Wire
Oct-17-19 11:21AM  Merck to eliminate 500 jobs American City Business Journals
Oct-15-19 05:45PM  Merck (MRK) Gains But Lags Market: What You Should Know Zacks
05:33PM  BriaCell Announces Closing of Non-Brokered Private Placement of $568,444 GlobeNewswire
11:42AM  J&J (JNJ) Beats on Q3 Earnings as Sales Rise, Ups 2019 View Zacks
Oct-14-19 03:59PM  Johnson and Johnson Stock Still Significantly Undervalued InvestorPlace
10:10AM  Why Merck (MRK) is Poised to Beat Earnings Estimates Again Zacks
Oct-13-19 12:34PM  Make sure you 'can pay for it': What health care execs think about Medicare for All Yahoo Finance
Oct-11-19 02:09PM  A cancer patient's journey to the cutting edge of cancer therapy American City Business Journals
Oct-10-19 11:15AM  Seattle Genetics Up More Than 20% in 3 Months: Here's Why Zacks
10:53AM  Merck CEO: Stepping down from Trump council was 'not a political issue' Yahoo Finance
10:27AM  Pharma industry is 'right in the crosshairs,' Merck CEO Kenneth Frazier says Yahoo Finance
10:23AM  Top Ranked Growth Stocks to Buy for October 10th Zacks
10:16AM  Merck CEO Kenneth Frazier: How innovation saves lives Yahoo Finance Video
08:53AM  4 Stocks From Highest Job-Creating Sectors in September Zacks
12:00AM  Yahoo Finance All Markets Summit: Generational Opportunities Yahoo Finance Video
Oct-09-19 04:52PM  WATCH: Yahoo Finance All Markets Summit: Generational Opportunities Yahoo Finance
11:15AM  J&J Ordered by Philadelphia Jury to Pay $8B in Risperdal Case Zacks
Oct-08-19 07:00PM  BriaCell Therapeutics Corp. to File Amendment to Management Information Circular GlobeNewswire
05:45PM  Merck (MRK) Stock Moves -1.33%: What You Should Know Zacks
10:07AM  Merck CEO Ken Frazier set to open Yahoo Finance's All Markets Summit Yahoo Finance
10:02AM  Verastem's (VSTM) Copiktra Gets Orphan Drug Designation Zacks
08:00AM  Merck Issues 2018/2019 Corporate Responsibility Report Business Wire
03:43AM  The Zacks Analyst Blog Highlights: General Dynamics, Merck, Progressive, ServiceNow, and Emerson Zacks
Oct-07-19 03:04PM  Top Analyst Reports for General Dynamics, Merck & Progressive Zacks
10:26AM  Wall Street Loves These Strong Buy Dividend Stocks TipRanks
10:05AM  The Zacks Analyst Blog Highlights: J&J, AstraZeneca, Roche, Glaxo and Merck Zacks
09:08AM  Novo Nordisk Focuses on Pipeline Development Amid Competition Zacks
08:48AM  Merck KGaA completes acquisition of Versum Materials Reuters
06:30AM  BriaCell Doses First Patient in Phase I/IIa Study Evaluating Bria-IMT in Combination with INCMGA00012 and Epacadostat in Patients with Advanced Breast Cancer GlobeNewswire
Oct-04-19 05:33PM  US Indexes Close Higher Friday After Volatile Week GuruFocus.com
11:11AM  Pharma Stock Roundup: JNJ's Opioid Settlement, FDA Updates for AZN, GSK, MRK, RHHBY Zacks
11:03AM  Here is Hedge Funds 30th Most Popular Stock Pick Insider Monkey
10:45AM  Gilead's Descovy HIV Regimen Gets FDA Nod for Label Expansion Zacks
08:14AM  Buying Merck? Here's the One Technical Level to Watch TheStreet.com
Oct-03-19 03:49PM  Biotech Stock On The Radar: FDA Verdict Ahead For Pfenex's Osteoporosis Biosimilar Benzinga
12:32PM  Pres. Trump to expand private Medicare Advantage program Yahoo Finance Video
11:45AM  What's Behind PDS Biotech's Rally? Benzinga
11:22AM  Merck's Pediatric Filings for Dificid Get FDA's Priority Review Zacks
Oct-02-19 09:15AM  Why Merck (MRK) is a Great Dividend Stock Right Now Zacks
07:05AM  AstraZeneca's Triple-Combo COPD Inhaler Gets CRL From FDA Zacks
06:45AM  Mercks KEYTRUDA® (pembrolizumab) Now Approved as Monotherapy in China for First-Line Treatment of Certain Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) Whose Tumors Express PD-L1 Business Wire
06:30AM  FDA Accepts Two Applications for Mercks DIFICID® (fidaxomicin) to Treat Children Aged Six Months Up to 18 years with Clostridium difficile Infections Business Wire
04:19AM  Merck Sees Hammer Chart Pattern: Time to Buy? Zacks
Oct-01-19 05:45PM  Merck (MRK) Stock Moves -0.68%: What You Should Know Zacks
04:42PM  Immunomedics (IMMU) Reports Interim Urothelial Cancer Data Zacks
11:45AM  Seattle Genetics Up on Positive Data From Bladder Cancer Study Zacks
09:51AM  AstraZeneca/Merck's Lynparza Positive in Prostate Cancer Study Zacks
06:55AM  Merck to Hold Third-Quarter 2019 Sales and Earnings Conference Call on October 29 Business Wire
06:30AM  Note from Chairman of BriaCell Therapeutics October is Breast Cancer Awareness Month GlobeNewswire
Sep-30-19 05:48PM  US Indexes Close Higher on the Last Day of September GuruFocus.com
04:47PM  Stocks - Apple Helps S&P Rally as a Quarter of Struggles Ends Investing.com
01:13PM  Movers And Shakers At ESMO 2019: Immunomedics, G1 Therapeutics, Seattle Genetics And More Benzinga
01:05PM  US STOCKS-Apple-led tech rally drives Wall Street higher Reuters
11:40AM  US STOCKS-Wall Street rises as Apple leads rally in technology shares Reuters
11:13AM  Glaxo's Zejula Betters PFS in First-Line Ovarian Cancer Study Zacks
10:59AM  AstraZeneca/Merck's Lynparza Improves PFS in Frontline Study Zacks
10:30AM  LYNPARZA® (olaparib) More Than Doubled Median Radiographic Progression-Free Survival (rPFS) in BRCA1/2 or ATM Metastatic Castration-Resistant Prostate Cancer vs. Standard of Care (7.4 vs. 3.6 months) Business Wire
06:55AM  Merck to Present at the 2019 Cantor Fitzgerald Global Healthcare Conference Business Wire
06:47AM  Do Institutions Own Merck & Co., Inc. (NYSE:MRK) Shares? Simply Wall St.
06:45AM  Pivotal RESTORE-IMI 2 Phase 3 Study of Mercks RECARBRIO (imipenem, cilastatin, and relebactam) in Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia (HABP/VABP) Met Primary Endpoint Business Wire
05:23AM  AstraZeneca, Merck ovarian cancer treatment improves progression-free survival Reuters
Sep-29-19 03:01PM  The Week Ahead In Biotech (Sept. 29-Oct. 5): Conference Presentations, IPOs Hit Top Gear Benzinga
10:30AM  Mercks KEYTRUDA® (pembrolizumab) Plus Chemotherapy Showed Statistically Significant Increase in Pathological Complete Response Versus Chemotherapy as Neoadjuvant Therapy in Early-Stage Triple-Negative Breast Cancer (TNBC) Business Wire
02:30AM  Final Study Results Evaluating KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Combination Treatment in Advanced Endometrial Cancer Presented at ESMO 2019 Congress Business Wire
Sep-28-19 10:30AM  LYNPARZA® (olaparib) Phase 3 PAOLA-1 Trial Significantly Increased Progression-Free Survival as First-Line Maintenance Treatment with Bevacizumab for Newly-Diagnosed Advanced Ovarian Cancer Business Wire
10:30AM  Bristol-Myers immunotherapy combo outperforms chemo in lung cancer survival -study Reuters
Sep-27-19 07:24PM  US Indexes Close Lower Friday GuruFocus.com
05:38PM  AbbVie (ABBV) Gets FDA Nod for Label Expansion of HCV Drug Zacks
05:33PM  IntelGenx (IGXT) Resubmits NDA for Migraine Candidate to FDA Zacks
02:00AM  New Data for BAVENCIO® (avelumab) for Advanced Cancers to Be Presented at ESMO 2019 PR Newswire
Sep-26-19 02:23PM  Pro Advisor: Buy Stocks 'Left In The Dust' Instead Of IPOs Benzinga
12:05PM  Medicines Company's Inclisiran Succeeds in Pivotal Studies Zacks
11:59AM  Here's Why Sanofi (SNY) is Outperforming Its Industry Of Late Zacks
11:45AM  Here's Why AstraZeneca (AZN) is Outperforming Its Industry Zacks
11:16AM  Tyme Initiates Pivotal Stage of Pancreatic Cancer Study Zacks
10:16AM  10 Biggest Companies That Offer Pensions Insider Monkey
09:16AM  The Zacks Analyst Blog Highlights: Procter & Gamble, Visa, United Technologies, Walmart and Merck Zacks
09:00AM  BioLineRx Begins Part 2 of Phase I/IIa Study on Solid Tumors Zacks
Sep-25-19 06:18PM  Menlo (MNLO) Completes Enrollment in Phase II Pruritus Study Zacks
10:53AM  Bristol-Myers' Opdivo Gains Positive CHMP View for New Dose Zacks
08:25AM  5 Top Dow Stocks to Buy on the Dip for a Stronger Portfolio Zacks
06:30AM  BriaCell Appoints Immunology Expert, Dr. Cara L. Haymaker, to Scientific Advisory Board; BriaCell CEO to Lead Special Targeted Immunotherapy Issue in Prestigious Journals GlobeNewswire
12:37AM  Bristol-Myers Squibb Company -- Moody's: China's rising demand for drugs will fuel foreign pharma companies' growth into 2023 Moody's
Sep-24-19 05:45PM  Merck (MRK) Dips More Than Broader Markets: What You Should Know Zacks
04:51PM  Merck Financial Services GmbH -- Moody's announces completion of a periodic review of ratings of Merck KGaA Moody's
11:46AM  Bristol-Myers Squibb Company -- Moody's: China's rising demand for drugs will fuel foreign pharma companies' growth into 2023 Moody's
11:36AM  Clovis Gains Rights to Pre-Clinical Cancer Program for $12M Zacks
Sep-23-19 05:10PM  Getting technical on a Dow 30,000 call Yahoo Finance Video
Merck & Co., Inc. provides healthcare solutions worldwide. It operates in Pharmaceutical, Animal Health, Healthcare Services, and Alliances segments. The company offers therapeutic and preventive agents to treat cardiovascular, type 2 diabetes, chronic hepatitis C virus, HIV-1 infection, intra-abdominal, fungal infection, insomnia, and inflammatory diseases. It also provides neuromuscular blocking agents; cholesterol modifying medicines; and anti-bacterial and vaginal contraceptive products. In addition, the company offers products to prevent chemotherapy-induced and post-operative nausea and vomiting; treat non-small-cell lung, ovarian and breast, thyroid, cervical, and brain cancers; and prevent diseases caused by human papillomavirus, as well as offers vaccines for measles, mumps, rubella, varicella, shingles, rotavirus gastroenteritis, and pneumococcal diseases. Further, it provides antibiotic and anti-inflammatory drugs to treat infectious and respiratory diseases, fertility disorders, and pneumonia in cattle, bovine, and swine; vaccines for poultry; parasiticide for sea lice in salmon; and antibiotics and vaccines for fish. Additionally, the company offers companion animal products, such as ointments; diabetes mellitus treatment and anthelmintic products; products to treat fleas and ticks in dogs and cats; horse fertility management products; dog, cat, and horse vaccines; and products for protection against bites from fleas, ticks, mosquitoes, and sandflies. It has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Intec Pharma Ltd.; Nerviano Medical Sciences; Healthy Interactions, Inc.; Oncologie, Inc.; Themis Bioscience; I-MAB Biopharma Co., Ltd.; and 4D pharma plc. It serves drug wholesalers and retailers, hospitals, government agencies and entities, physicians, distributors, veterinarians, animal producers, and managed health care providers. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
DeLuca Richard R.EVP&Pres, Merck Animal HeallthAug 09Option Exercise0.006,427077,951Aug 12 05:13 PM
DeLuca Richard R.EVP&Pres, Merck Animal HeallthAug 09Sale85.096,427546,85071,524Aug 12 05:13 PM
DeLuca Richard R.EVP&Pres, Merck Animal HeallthAug 08Option Exercise0.0031,6990103,223Aug 12 05:13 PM
DeLuca Richard R.EVP&Pres, Merck Animal HeallthAug 08Sale85.0131,6992,694,78971,524Aug 12 05:13 PM
Davis Robert MEVP, Global Svcs & CFOJun 25Option Exercise0.00216,7180354,378Jun 27 05:05 PM
Davis Robert MEVP, Global Svcs & CFOJun 25Sale85.43216,71818,514,032137,660Jun 27 05:05 PM
Karachun Rita ASr. VP Fince-Global ControllerMay 10Option Exercise0.003,292022,412May 13 05:06 PM
Clyburn FrankEVP, Chief Commercial OfficerMay 10Option Exercise0.004,389071,993May 13 05:05 PM
Fleming MichaelSVP Chief Ethics & Com OfficerMay 10Option Exercise0.001,50903,317May 13 05:05 PM
Nally MichaelEVP, Chief Marketing OfficerMay 10Option Exercise0.001,81104,376May 13 05:06 PM
Clyburn FrankEVP, Chief Commercial OfficerMay 07Option Exercise39.2925,000982,25092,604May 09 06:11 PM
Clyburn FrankEVP, Chief Commercial OfficerMay 07Sale77.7325,0001,943,18367,604May 09 06:11 PM
Zachary JenniferEVP, General CounselMay 04Option Exercise0.005,77205,772May 07 07:42 PM
Nally MichaelEVP, Chief Marketing OfficerMay 04Option Exercise0.001,29802,935May 07 07:40 PM
Clyburn FrankEVP, Chief Commercial OfficerMay 04Option Exercise0.001,904068,542May 07 07:37 PM
Karachun Rita ASr. VP Fince-Global ControllerMay 04Option Exercise0.001,212019,717May 07 08:32 PM
Fleming MichaelSVP Chief Ethics & Com OfficerMay 04Option Exercise0.0069202,046May 07 08:32 PM
DeLuca Richard R.EVP&Pres, Merck Animal HeallthMay 03Option Exercise39.2935,0001,375,150106,064May 07 08:33 PM
DeLuca Richard R.EVP&Pres, Merck Animal HeallthMay 03Sale80.0035,0002,800,00071,064May 07 08:33 PM
Merck & Co., Inc.10% OwnerApr 08Buy16.004,121,68365,946,92812,955,016Apr 09 06:27 PM
Davis Robert MEVP, Global Svcs & CFOMar 25Option Exercise58.22192,57211,211,542330,232Mar 27 05:45 PM
Davis Robert MEVP, Global Svcs & CFOMar 25Sale82.38192,57215,863,119137,660Mar 27 05:45 PM
FRAZIER KENNETH CChairman, President & CEOMar 20Option Exercise39.29192,7367,572,597990,451Mar 20 06:49 PM
FRAZIER KENNETH CChairman, President & CEOMar 20Sale82.05192,73615,813,372797,715Mar 20 06:49 PM
FRAZIER KENNETH CChairman, President & CEOMar 13Option Exercise39.2918,725735,705816,440Mar 14 06:38 PM
FRAZIER KENNETH CChairman, President & CEOMar 13Sale82.0018,7251,535,454797,715Mar 14 06:38 PM
FRAZIER KENNETH CChairman, President & CEOMar 05Option Exercise39.296,961273,498804,676Mar 06 06:13 PM
FRAZIER KENNETH CChairman, President & CEOMar 05Sale82.006,961570,809797,715Mar 06 06:13 PM
FRAZIER KENNETH CChairman, President & CEOMar 04Option Exercise39.2913,144516,428810,859Mar 06 06:13 PM
FRAZIER KENNETH CChairman, President & CEOMar 04Sale82.0113,1441,077,875797,715Mar 06 06:13 PM
FRAZIER KENNETH CChairman, President & CEOFeb 22Option Exercise39.2953,9612,120,128745,911Feb 22 05:16 PM
FRAZIER KENNETH CChairman, President & CEOFeb 22Sale80.0253,9614,318,089691,950Feb 22 05:16 PM
FRAZIER KENNETH CChairman, President & CEOFeb 21Option Exercise39.2941,9921,649,866733,942Feb 22 05:16 PM
FRAZIER KENNETH CChairman, President & CEOFeb 21Sale80.0041,9923,359,452691,950Feb 22 05:16 PM
FRAZIER KENNETH CChairman, President & CEOFeb 19Option Exercise39.2942,7001,677,683734,650Feb 19 05:35 PM
FRAZIER KENNETH CChairman, President & CEOFeb 19Sale80.0242,7003,416,944691,950Feb 19 05:35 PM
FRAZIER KENNETH CChairman, President & CEOFeb 15Option Exercise39.2992,9133,650,552784,863Feb 19 05:35 PM
FRAZIER KENNETH CChairman, President & CEOFeb 15Sale80.0392,9137,436,162691,950Feb 19 05:35 PM
Karachun Rita ASr. VP Fince-Global ControllerFeb 14Option Exercise59.1664,6623,825,55180,837Feb 14 06:02 PM
Karachun Rita ASr. VP Fince-Global ControllerFeb 14Sale78.9664,6625,105,95116,175Feb 14 06:02 PM
WEEKS WENDELL PDirectorFeb 13Option Exercise24.305,000121,5005,100Feb 14 06:02 PM
WEEKS WENDELL PDirectorFeb 13Sale78.715,000393,548100Feb 14 06:02 PM
Chattopadhyay SanatExe V-P & Pres. MMDFeb 12Option Exercise38.1873,7272,815,241125,194Feb 14 06:02 PM
Chattopadhyay SanatExe V-P & Pres. MMDFeb 12Sale78.6273,7275,796,30651,467Feb 14 06:02 PM
BRUN LESLIE ADirectorFeb 08Option Exercise24.305,000121,5005,000Feb 11 05:33 PM
BRUN LESLIE ADirectorFeb 08Sale77.223,052235,6811,948Feb 11 05:33 PM
FRAZIER KENNETH CChairman, President & CEOFeb 05Option Exercise39.29231,5669,098,228923,516Feb 06 05:30 PM
FRAZIER KENNETH CChairman, President & CEOFeb 05Sale78.08231,56618,079,654691,950Feb 06 05:30 PM
PERLMUTTER ROGER MExe V-P & Pres, MRLNov 08Option Exercise44.98225,44310,140,426366,998Nov 08 04:31 PM
PERLMUTTER ROGER MExe V-P & Pres, MRLNov 08Sale75.27225,44316,967,967141,555Nov 08 04:31 PM
Gerberding Julie L.EVP Strat Comm, Gl Pub PolicyNov 07Option Exercise54.6836,2181,980,40082,481Nov 08 04:31 PM
Gerberding Julie L.EVP Strat Comm, Gl Pub PolicyNov 07Sale75.1436,2182,721,34846,263Nov 08 04:31 PM
Schechter Adam HEVP & Pres-Global Human HealthNov 01Option Exercise39.29277,87910,917,866277,879Nov 02 04:44 PM
Schechter Adam HEVP & Pres-Global Human HealthNov 01Sale73.81277,87920,510,9450Nov 02 04:44 PM
Watson AshleySVP Chief Ethics & Com OfficerOct 31Option Exercise58.3647,0362,745,21756,806Nov 01 05:07 PM
Watson AshleySVP Chief Ethics & Com OfficerOct 31Sale74.3347,0363,496,1589,770Nov 01 05:07 PM
DeLuca Richard R.EVP&Pres, Merck Animal HealthOct 30Option Exercise34.1925,467870,71782,135Nov 01 05:07 PM
DeLuca Richard R.EVP&Pres, Merck Animal HealthOct 30Sale72.0025,4671,833,73956,668Nov 01 05:07 PM
open in yahoo | open in reuters | open in google